1. Homepage
  2. Equities
  3. Canada
  4. Toronto Stock Exchange
  5. Resverlogix Corp.
  6. News
  7. Summary
    RVX   CA76128M1086

RESVERLOGIX CORP.

(RVX)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Resverlogix Corp. in Active Discussions with Kingdom of Morocco?s Ministry of Health for Launch of COVID-19 Clinical Studies with First-In-Class Drug Apabetalone

11/01/2021 | 07:30am EDT

Resverlogix Corp. announced that it is in active discussions with the Kingdom of Morocco?s Ministry of Health for possible Phase 2 COVID-19 clinical studies within their hospitals using first-in-class drug ? apabetalone. Following Health Canada?s approval for the company?s COVID-19 clinical trials, it has been actively working with hospitals and ministries to commence COVID-19 trials globally. On October 12, 2021, the company received ethics committee approval for COVID-19 clinical trials in Western Canadian sites. Additionally, a Phase 3 COVID-19 trial in the US is anticipated to commence in coming months based on final protocol approval. Phase 2 Trial Overview? Canada/Brazil: study participants will be made up of patients hospitalized with confirmed COVID-19 cases. Participants will either receive twice daily doses of apabetalone for up to 4 weeks alongside standard of care, compared to standard of care alone. The primary outcome measure of the study will be change in the World Health Organization (WHO) Ordinal Scale for Clinical Improvement. A total of 100 patients are expected to be enrolled at multiple sites in Canada and Brazil.


© S&P Capital IQ 2021
All news about RESVERLOGIX CORP.
05/20RESVERLOGIX : Annual Meeting of Shareholders Notice-and-Access Notification to Shareholder..
PU
05/13Resverlogix Corp. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/09Resverlogix Announces Type C Meeting with FDA For Phase 3 High-Risk COVID-19 Outpatient..
MT
05/09U.S. Food and Drug Administration Grants Resverlogix Corp. Request for Type C Meeting t..
CI
05/09RESVERLOGIX BRIEF : Announces Type C Meeting with FDA for CORAL, a Phase 3 High-risk COVID..
MT
05/09Resverlogix Announces Type C Meeting with FDA for CORAL, a Phase 3 High-risk COVID-19 O..
GL
05/09Resverlogix Announces Type C Meeting with FDA for CORAL, a Phase 3 High-risk COVID-19 O..
AQ
04/19Resverlogix Details One-Year Extension of Debenture
MT
04/19Resverlogix Announces One-Year Extension of Debenture
AQ
04/08RESVERLOGIX : Notice of Annual and Special Meeting
PU
More news
Financials
Sales
Net income
Net Debt
P/E ratio
Yield
Capitalization 54,2 M 54,2 M -
EV / Sales -1
EV / Sales 0
Nbr of Employees -
Free-Float 40,4%
Chart RESVERLOGIX CORP.
Duration : Period :
Resverlogix Corp. Technical Analysis Chart | RVX | CA76128M1086 | MarketScreener
Technical analysis trends RESVERLOGIX CORP.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Managers and Directors
Donald J. McCaffrey Chairman, President, CEO & Secretary
Anthony Brad Cann Chief Financial Officer
Norman C. W. Wong Chief Scientific Officer
Jan O. Johansson Senior Vice President-Medical Affairs
Michael T. Sweeney Senior Vice President-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
RESVERLOGIX CORP.-45.10%54
GILEAD SCIENCES, INC.-11.38%80 715
REGENERON PHARMACEUTICALS, INC.8.63%73 916
VERTEX PHARMACEUTICALS22.26%68 665
WUXI APPTEC CO., LTD.-22.20%40 017
BIONTECH SE-40.07%37 546